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thoroughly investigated. Numerous patient­
­related, lesion ­related, procedural and postpro­
cedural factors are related to the occurrence of ST 
(TABLE 2). In the early phase, within 30 days after 
PCI, procedural factors are most likely responsi­
ble for ST, such as underexpansion, stent malap­
position, residual dissection, tissue prolapse, and 
medial fracture.6,7 Since the cause of early ST is 
mostly procedure related, the pathological find­
ings are similar between various stents. Besides 
these procedural factors, stenting in acute coro­
nary artery disease with high levels of thrombin 
is associated with high risk of ST.8 In the early 
phase, platelets are exposed to nonendothelial­
ized stent struts, thus optimal inhibition of plate­
let activation is the key factor of preventing early 
ST.7 Clopidogrel resistance and discontinuation 
of dual antiplatelet therapy (DAPT) are essential 
risk factors of early ST.9
Late and very late stent thrombosis ST beyond 
30 days after stent implantation is associated 
with delayed re ­endothelialization character­
ized by persistence of fibrin and uncovered stent 
struts.6,10 It takes at most 3 months for BMS to 
be covered by the endothelium, while endotheli­
alization of early ­generation drug ­eluting stents 
(DESs) can take longer.6 The delayed arterial heal­
ing in DES is likely responsible for the higher rates 
of late ST in early ­generation DES.10,11
Introduction In the 1980s, the bare ­metal coro­
nary artery stent (BMS) was introduced, which 
has dramatically improved the safety and efficacy 
of percutaneous coronary intervention (PCI).1,2 
Although permanent scaffolding of the coronary 
vessel overcame the risk of abrupt vessel closure 
by dissection, acute closure of the stent by oth­
er mechanisms was recognized as an important 
complication. Acute closure of the metallic endo­
prosthesis, the so ­called stent thrombosis (ST), is 
associated with high rates of morbidity and mor­
tality.3 Therefore, stent technology, implantation 
technique, and adjunct pharmacological therapy 
have been constantly adjusted to reduce the risk 
of ST. Now, 40 years after the first coronary bal­
loon angioplasty, and despite all the advancement, 
percutaneous coronary therapy without resteno­
sis or ST has not yet become a reality. 
Definition of stent thrombosis In order to be able to 
compare the results of different clinical trials, the Ac­
ademic Research Consortium defined ST according 
to various levels of certainty (TABLE 1).4 The sensitiv­
ity and specificity of adjudicated ST event depends 
on the level of certainty.5 In addition, the Academ­
ic Research Consortium made a classification of ST 
based on the time of occurrence (TABLE 1).4
Pathophysiology of stent thrombosis Early stent 
thrombosis The mechanisms of ST have been 
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ABSTRACT
The percutaneous coronary intervention (PCI) has undergone rapid evolution over the last 40 years and has 
become one of the most widely performed medical procedures. The introduction of intracoronary stents 
has improved the safety and efficacy of PCI. However, with the advent of stenting, a new potentially fatal 
enemy has emerged: stent thrombosis. Ever since, adjunct pharmacological therapy, stent technique, and 
technology have been adjusted to reduce the risk of stent thrombosis. The aim of the present article is to 
provide an overview of the past, present, and future aspects of PCI in relation to stent thrombosis.
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Colombo et al13 introduced DAPT with low ­dose 
aspirin and thienopyridine, and optimized stent 
implantation using high ­pressure balloon infla­
tion under intravascular ultrasound imaging. This 
combination led to an ST rate of 1.6% at 6 ­month 
follow ­up and favored the dissemination of BMS 
use. However, stent implantation causes arterial 
injury resulting in excessive neointimal prolifera­
tion, which may result in restenosis.14 Restenosis, 
which leads to a need for revascularization, oc­
curred in up to 30% of the patients treated with 
BMS and is the key limitation of BMS.
Early ‑generation drug ‑eluting stents To address 
the main limitation of BMS, metallic stents are 
coated with cytostatic drugs. The early ­generation 
DES consists of 3 components: a stainless ­steel 
stent platform with strut thickness of 130 to 
150 µm, an antiproliferative agent, and a dura­
ble polymer coating. The polymer coating allows 
an effective and controlled antiproliferative drug 
release. The first trials showed that, indeed, DES 
markedly reduced restenosis and the need for re­
vascularization at 6 ­month follow ­up compared 
with BMS.15,16 The Initial Double ­Blind Drug­
­Eluting Stent vs Bare ­Metal Stent Study (RAVEL) 
showed a reduction of 100% in restenosis (lumi­
nal narrowing of 50% or more) at 6 months with 
sirolimus ­eluting stent as compared with BMS 
(0% vs 26.6%, respectively).15 However, the ini­
tial enthusiasm was slowly tempered by growing 
concerns over an increased risk of late and very 
late ST. Later, registry data published by Daemen 
et al17 demonstrated a steady risk for ST of 0.6% 
per year after DES implantation. Thus, the first­
­generation DES overcame the shortcomings of 
BMS by reducing the restenosis rate but intro­
duced another problem, namely, late and very 
late ST. Pathological studies elucidated the un­
derlying pathophysiology of these adverse events. 
The durable polymer, the thickness of the stent 
struts, the dose of the antiproliferative drug and 
its release kinetics were important factors con­
tributing to the occurrence of ST after DES im­
plantation,6 in particular the durable polymer. 
The durable polymer could result in chronic ar­
terial wall inflammation and impaired endotheli­
al healing of the stented segment, which increas­
es the risk of ST.6
Present New ‑generation drug ‑eluting stents New­
­generation DESs have improved antiproliferative 
drug release kinetics, thinner stent struts, and 
more biocompatible or biodegradable polymer 
coatings. The new ­generation DESs are based on 
novel metallic alloys, such as cobalt ­chromium 
and platinum ­chromium, allowing thinner stent 
struts (50–100 µm) while maintaining an ade­
quate radial strength. Thinner stent struts (<100 
µm) improve hemodynamic flow with a relative­
ly lower shear stress over the struts, favoring 
vessel healing of the stented segment.18 In ad­
dition, thinner stent struts have a lower degree 
of thrombogenicity in comparison with thicker 
Other mechanisms in addition to delayed heal­
ing are important in the pathophysiology of very 
late ST. Hypersensitivity reaction due to polymer 
promotes macrophage reaction along with fibrin 
deposition and is associated with very late ST. 
Also extensive fibrin deposition leads to stent 
malapposition and is associated with ST.6 Hyper­
sensitivity reaction is rarely observed in patients 
with very late ST of BMS.
In addition, neoatherosclerosis of the stented 
segment is observed in patients with very late 
ST. Neoatherosclerosis following stent implanta­
tion is likely multifactorial. Newly formed athero­
sclerotic plaques contain peri ­strut foamy mac­
rophage clusters or fibroatheromas with necrot­
ic core formations. The incidence of neoathero­
sclerosis is greater in lesions associated with DES 
than those with BMS.6
Past Bare ‑metal stents In the early days of in­
tracoronary stenting, with low ­pressure infla­
tion and single antiplatelet therapy, the use of 
BMSs was associated with approximately 20% of 
ST cases.1 The use of aspirin in combination with 
warfarin reduced the rate of ST to 3.5% but led 
to more hemorrhagic complications.2,12 In 1995, 
TABLE 1 Definition of stent thrombosis according to the Academic Research 
Consortium
Level of certainty
Definite ST Angiographic or pathological confirmation of occlusion 
within the peri ‑stent region with clinical evidence of fresh 
thrombus
Probable ST Any unexpected death <30 days after PCI
OR
Any MI with documented acute ischemia in the territory of 
stented segment without angiographic confirmation of ST
Possible ST Any unexplained death >30 days after PCI
Timing
Early Acute ST <24 hours
Subacute ST 24 hours to 30 days
Late ST 31 days to 1 year
Very late ST >1 year
Abbreviations: MI, myocardial infarction; PCI, percutaneous coronary intervention; ST, 
stent thrombosis
TABLE 2 Predictors of stent thrombosis
Patient ‑related factors Acute coronary syndromes, diabetes mellitus, smoking, 
renal failure, LVEF <30%, malignancy, prior brachytherapy, 
peripheral artery disease, nonadherence to antiplatelet 
therapy
Lesion ‑related factors Lesion length, vessel diameter, complex lesions (bifurcation, 
chronic total occlusion), thrombus, saphenous vein grafts
Procedural factors Stent undersizing/underexpansion, stent malapposition, 
stent deployment in necrotic core, dissection, stent length, 
overlapping stents
Postprocedural 
factors
TIMI flow grade <2 after PCI, premature cessation of 
antiplatelet therapy
Abbreviations: LVEF, left ventricular ejection fraction; TIMI, Thrombolysis in Myocardial 
Infarction; others, see TABLE 1
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such as abnormal vasomotion and neointimal 
proliferation, which contribute to the risk of 
very late ST,6,10,22 bioresorbable vascular scaf­
folds (BVSs) have been developed. BVSs were de­
signed to provide transient mechanical support 
with drug delivery similar to that of DES during 
the required period, followed by complete bio­
resorption over several years. In the absence of 
a rigid metallic cage, there would be no potential 
triggers for thrombosis, such as uncovered stent 
struts, malapposition, and drug or durable poly­
mer. Thereby, complete bioresorption can theo­
retically facilitate the restoration of the vasomo­
tor tone, adaptive shear stress, late luminal en­
largement, and late expansive remodeling.23‑25 All 
this contributes to a better vascular healing and 
reduces the need for revascularization.
Early studies of the Absorb BVS (Abbott Vas­
cular, California, United States) noted noninfe­
riority of safety and efficacy at 1 ­year follow­up 
compared with metallic DES.26 This led to approv­
al by the Food and Drug Administration and clin­
ical adoption of the device. However, concerns re­
garding scaffold thrombosis emerged from the re­
sults of the Amsterdam Investigator ­Initiated Ab­
sorb Strategy All ­Comers Trial (AIDA). Absorb had 
more device ­related ST with a mean follow ­up of 
707 days compared with metallic DES (3.5% vs 
0.9%; P <0.001).27 Meta ­analyses of the Absorb 
struts. Moreover, stents with thinner struts cause 
less vessel injury at implantation. Penetration of 
necrotic tissue is associated with the occurrence 
of ST.19 The effect of stent strut in the vessel wall 
on blood flow and the biochemical reactions are 
depicted in FIGURE 1.
In addition, new ­generation DESs have been 
developed with improved biocompatibility of 
the polymer coating. Also, some stents have 
been developed with a biodegradable polymer. 
Once the antiproliferative drugs are completely 
released, the polymer coating has no function. 
Therefore, the biodegradable polymers are fully 
resorbed by hydrolysis after the completion of 
drug release. Several new ­generation DESs have 
been designed and approved for European use.
Numerous studies have shown a favorable 
safety and efficacy of new ­generation DES com­
pared with early ­generation DES.20,21 Some meta­
­analyses have also shown that new ­generation 
DESs have a decreased risk of ST compared with 
BMSs.21 Especially the XIENCE durable–polymer­
­based everolimus ­eluting stent showed improved 
safety compared with other stents.21 However, the 
risk of ST remains and is very unpredictable, so 
the search for the optimal stent design continues.
Bioresorbable vascular scaffolds To overcome 
the shortcomings of a permanent metallic stent, 
FIGURE 1 Shear stress. The implanted stent strut and the changes in flow in the vicinity of the strut are shown. The red blood cells (RBCs) (red filled 
circular structures) tend to accumulate towards the center of the lumen; the platelets (grey filled circles) are pushed to the vessel wall by the RBCs. 
When they move in a faster flow zone passing over the strut top surfaces, the platelets are elongated and activated. After crossing the faster flow zone, 
the platelets enter a reversing flow zone. Since the flow velocity decreases in these reversing flow zones, platelets resume their original discoid shapes 
and release several growth factors. The ESS bar codes the shear stress levels over the intimal layer and the strut. The velocity bar codes the velocity of 
the flow streamlines in the vessel lumen. 
Abbreviations: ADP, adenosine diphosphate; BVS, bioresorbable vascular scaffolds; FGF ‑β, fibroblast growth factor β; GP IIb/IIIa, glycoprotein IIb/IIIa; 
ICAM ‑1, intercellular adhesion molecule 1; IFN ‑γ, interferon γ; IL ‑1, interleukin 1; LDL ‑C, low ‑density lipoprotein cholesterol; MMP, matrix 
metalloproteinase; NO, nitric oxide; ROS, reactive oxygen species; TNF ‑α, tumor necrosis factor α; VCAM ‑1, vascular cell adhesion molecule 1; vWF, 
von Willebrand factor
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mechanisms and frequency of very late scaffold 
thrombosis are illustrated in FIGURE 2.
Intracoronary imaging Emergency PCI is the pre­
ferred treatment for ST. Coronary angiogra­
phy provides a 2 ­dimensional representation of 
the 3 ­dimensional arteries. It shows luminal di­
mensions and characteristics without providing 
any information on the arterial wall. This modal­
ity is also suboptimal in identifying stent under­
expansion, malapposition, residual dissection, 
thrombus or plaque protrusion, all known trig­
gers for ST. Intravascular ultrasound (IVUS) and 
optical coherence tomography (OCT) overcome 
these limitations and can visualize the underlying 
mechanisms causing ST.41,42 Intravascular imaging 
with IVUS or OCT can be safely performed after 
stabilization of the clinical status of the patient. 
The underlying cause of ST influences the treat­
ment of the affected segment. When stent malap­
position is the cause of ST, high ­pressure balloon 
angioplasty suffices, but when stent edge dissec­
tion is the underlying problem, implementation 
of a new stent is advised.
In addition, intravascular imaging after PCI will 
optimize stent implantation by immediately de­
tecting stent underexpansion, malapposition, or 
edge ­related dissections and thereby, in theory, 
will reduce the change of ST. Large observation­
al cohort studies, randomized trials, and meta­
­analyses have shown that IVUS ­guided stent im­
plantation reduces the rate of major adverse car­
diac events, including ST, compared with angiog­
raphy guidance alone.43,44 Despite these findings 
and guideline recommendations,45 IVUS ­guided 
PCI is rarely used. Low resolution (150–200 µm), 
slow pullback, and absence of accurately pow­
ered randomized trials are often mentioned as 
the grounds for the low levels of adoption of IVUS 
in standard care.
studies confirmed these results.28,29 Ali et al28 per­
formed a patient ­level meta ­analysis of the Ab­
sorb randomized trials and found higher rates of 
device thrombosis during 3 ­year follow ­up with 
BVS (2.4% vs 0.6%; P = 0.001). After these ob­
servations, Abbott has ended commercial sales 
of the Absorb BVS.  
The mechanisms of early scaffold thrombosis 
seems to be similar to that of early ST after BMS 
or DES implantation, including procedural fac­
tors such as device underexpansion, malapposi­
tion, and undersizing.30‑32
Delayed healing with uncovered struts of 
the stented segment was the primary cause of 
late ST in first­generation DESs with thick struts 
(~140 µm).33 Because the polymeric structure of 
the BVS is not as strong as metal, Absorb BVS 
have thick struts (157 µm) to improve its radi­
al strength. In addition to these thick struts, 
other mechanisms seemed to contribute to late 
and very late scaffold thrombosis. Malapposi­
tion and scaffold discontinuity are mostly asso­
ciated with late or very late scaffold thrombo­
sis.34,35 Scaffold discontinuity suggests an unfa­
vorable scaffold bioresorption progress. Before 
the struts disappear, they lose their structural 
integrity which might lead to intraluminal dis­
mantling of the scaffold.36 The discontinuous 
struts can penetrate into the lumen and cause 
disruption of the laminarity of flow with sub­
sequent activation of the coagulation cascade, 
which may end up in thrombus formation and 
vessel occlusion.37‑39 Even after optimal implan­
tation of BVS, the thicker quadratic struts may 
induce disruption in a local microhemodynam­
ic environment and result in lower shear stress 
zones in the vicinity of the struts engender­
ing a well ­established area for thrombus for­
mations, which entails thinner and streamlined 
design of the struts.40 The different underlying 
FIGURE 2  
Representative images 
and frequencies (%) of the 
mechanisms underlying 
very late scaffold 
thrombosis, including 
scaffold discontinuity (A); 
malapposition (B), 
neoatherosclerosis (C), 
underexpansion (D), 
uncoverage (E), edge‑ 
‑related progression (F). 
Light attenuation due to 
lipid accumulation within 
the neointima of 
the scaffold (asterisks) 
(reproduced with 
permission from Yamaji et 
al)34 
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in Treatment of De Novo Coronary Artery Le­
sions)58 and up to 6 months in TAXUS ­IV tri­
al (Treatment of De Novo Coronary Disease Us­
ing a Single Paclitaxel ­Eluting Stent).59 The dura­
tion of DAPT was prolonged to reduce the rates 
of restenosis and associated clinical events, but 
the optimal duration has not been investigated 
in randomized clinical trials. Once the increased 
risk of late ST after early ­generation DES implan­
tation was noticed, the duration of DAPT was 
prolonged even further to 1 year after PCI. This 
led to the guidelines’ recommendation of DAPT 
for at least 6 months following DES implanta­
tion in patients with stable coronary artery dis­
ease and 12 months in those with acute coro­
nary syndromes.60 These recommendations still 
apply today. However, they are based on weak 
evidence, and the optimal duration of DAPT re­
mains undetermined.
To provide evidence supporting the consen­
sus guideline recommendations, extensive re­
search investigating the optimal duration of DAPT 
have been done. These studies have been focused 
on 2 main strategies: abbreviated and extend­
ed DAPT regimens. The duration of prolonged 
DAPT ranged from 18 months to 4 years, which 
was compared with a 12 ­month DAPT regimen. 
Similar rates of adverse events between the reg­
imens were observed in all trials. The small ben­
efit in terms of very late ST prevention does not 
seem to be justified against the risk of bleeding 
related to DAPT prolongation.61‑64
Around 6% of the patients with acute coronary 
syndrome do not respond to clopidogrel therapy.65 
Buanamici et al9 showed this nonresponsiveness 
to be independently associated with a higher risk 
of ST. The advent of novel potent P2Y12 receptor 
inhibitors and the refinements in DES technol­
ogy have resulted in a shift from the belief that 
DAPT duration should be extended to abbreviat­
ed DAPT. In studies on shorted DAPT, 12 ­month 
DAPT was, in general, compared with either 3­ or 
6­month DAPT. All those trials demonstrated 
noninferiority but no superiority of the abbreviat­
ed DAPT regimen.66‑69 Of note, the results should 
be carefully interpreted due to the use of different 
definitions of major adverse cardiac events and 
major bleeding. In addition, the trials tested for 
noninferiority of net adverse cardiac events be­
tween DAPT regimens. In this approach, minor 
bleeding and ST obtain the same value.
In addition, it is thought that ticagrelor may also 
provide inhibition of the cyclooxygenase ­1 path­
way.70 If this is correct, ticagrelor monotherapy 
will maintain efficacy compared with the com­
bined use of aspirin and ticagrelor while improv­
ing safety. Two worldwide randomized trials of 
ticagrelor monotherapy are ongoing, and the re­
sults will be presented soon.71,72
Future perspectives Overall, the impressive de­
velopment of PCI technology—particularly cor­
onary stents—has changed the standard treat­
ment of ischemic heart disease. Nowadays, 
OCT is a newer intravascular imaging meth­
od and provides high­resolution images (10–20 
µm).46,47 OCT is more accurate than IVUS in de­
tecting morphological details during PCI, in­
cluding malapposition, plaque prolapse, residu­
al thrombus, and residual dissections after stent 
implantation. During follow ­up after PCI, OCT is 
also superior to IVUS for the assessment of neo­
intimal thickness, strut apposition, and strut 
coverage.48,49 Nonetheless, fewer clinical stud­
ies of OCT ­guided stenting have been conduct­
ed. Prati et al50 showed that angiography plus 
OCT ­guidance resulted in lower rates of cardiac 
deaths, myocardial infarction (MI), and the com­
posite endpoint of cardiac death, MI, or repeat re­
vascularization at 1 ­year follow ­up compared with 
coronary angiography guidance. The addition of 
the OCT guidance was independently associat­
ed with a lower risk of cardiac death or MI (odds 
ratio, 0.49; 95% confidence interval 0.25–0.96; 
P = 0.037). However, previous studies showed 
that OCT may lead to the choice of a smaller stent 
diameter and is associated with smaller lumen 
compared with IVUS or coronary angiography.51 
Moreover, OCT required an additional intracor­
onary injection of contrast media to enable visu­
alization.52 The volume of contrast media should 
be taken into account since contrast nephropa­
thy is one of the major causes of in ­hospital and 
long ­term mortality and morbidity after PCI.53 
Therefore, OCT is not yet a standard procedure 
during PCI.
A recent randomized clinical trial showed that 
a novel OCT ­based stent sizing strategy resulted 
in a similar minimum lumen area as IVUS ­guided 
stent implantation.52 Whether this new strategy 
with OCT will result in better clinical outcomes is 
unknown. This issue will be addressed in the up­
coming ILUMIEN IV randomized trial.
Antiplatelet therapy Antiplatelet therapy has be­
come essential after PCI for primary prevention of 
ST and secondary prevention of ischemic throm­
botic events. In 1977, when the first in ­man per­
cutaneous transluminal coronary angioplasty 
was performed, aspirin was given before the pro­
cedure, followed by warfarin administered after 
the procedure and continued for 6 to 9 months.54 
The use of aspirin in combination with warfarin 
improved clinical outcomes with a reduction of 
the ST rate from 20% to 3.5%, but this combina­
tion led also to excessive bleeding complications.2
Colombo et al13 and Schömig et al55 reported 
that treatment with DAPT (aspirin plus ticlopi­
dine) up to 1 month after PCI reduced the inci­
dence of both ST and hemorrhagic complications 
compared with anticoagulant therapy (warfarin 
plus aspirin).56 Clopidogrel was found to be a saf­
er alternative to ticlopidine.57 DAPT with aspirin 
plus clopidogrel became the standard therapy 
following PCI. When DESs were investigated for 
the first time, duration of DAPT was prolonged 
to 3 months in the SIRIUS study (Sirolimus­
­Coated BX VELOCITY Balloon ­Expandable Stent 
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secondary prevention of ischemic thrombotic 
events. A premature cessation of DAPT is a strong 
predictor of ST.73 It takes time before the stent is 
re ­endothelialized, and until then, the discountin­
ation of DAPT can be fatal and lead to ST. Be­
cause ST is associated with a high mortality rate 
of around 20%,3 cessation of DAPT should always 
be decided in consultation with an intervention­
al cardiologist. The duration of DAPT depends 
on the indication for PCI, type of stent, compli­
cations that may have occurred during PCI, and 
contraindications.80,81 The interventional cardi­
ologist has the expertise to assess the risks of 
DAPT cessation.
Moreover, the choice of treatment for signif­
icant coronary artery disease will be also influ­
enced by other needed interventions or treat­
ments. If a  patient needs chemotherapy or 
surgery—treatments with high risk of bleed­
ing—the choice of stent will be different from 
that in a patient without these upcoming treat­
ments.82 Collaboration between different special­
ists is important for patients with multimorbidity.
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new ­generation DESs are the standard of care 
for patients undergoing PCI. However, although 
uncommon, ST still occurs and is feared due to 
the strong association with mortality.3 Thereby, 
ST is still unpredictable. The permanent metal­
lic cage represents a potential trigger for ST in 
the years after implantation. This is particularly 
relevant in otherwise healthy patients with a long 
life expectancy. Whether liberation of the metal­
lic stent and restoration of the vascular physiolo­
gy may translate into clinically meaningful ben­
efits without ST will be evaluated in future stud­
ies after advances in the scaffold technologies 
have been made.
In addition, an improvement of stenting in 
the subgroups of clinically or anatomically com­
plex patients is needed. Patients with diabetes are 
characterized by more advanced and complex cor­
onary artery disease. Despite the improvement in 
metallic stent technology, diabetes remains an in­
dependent predictor of ST.73 Clinical outcomes 
of patients with diabetes might be improved by 
increased antirestenotic potency of the metallic 
stent. Sardella et al74 showed promising results 
of a dedicated DES with antiproliferative agent 
amphilimus—a formulation of sirolimus and or­
ganic acids—used in diabetic patients. Howev­
er, these results require further confirmation in 
large ­scale randomized clinical trials.
The  treatment strategy for lesions in the 
small vessels, in ­stent restenosis, and bifurca­
tion lesions also needs improvement. Recently, 
sirolimus ­coated balloons have been developed. 
Preclinical trials showed encouraging results for 
this method.75 There are several ongoing trials in­
vestigating the use of sirolimus ­coated balloons 
for complex lesions instead of DESs. A registry of 
277 patients with complex lesions demonstrat­
ed that sirolimus ­coated balloon angioplasty is 
effective in complex lesions (EuroPCR presenta­
tion, 2016).76 If the other trials show similar re­
sults, drug ­coated balloons will get a more resil­
ient role in PCI.
The optimal duration of DAPT is still a mat­
ter of debate. Not only should the optimal PCI 
strategy be personalized by considering the an­
atomical aspects and comorbidities in individual 
patients, but also the duration of DAPT should 
be tailored based on the assessment of the risk –
benefit ratio. Several risk scores have been creat­
ed and validated,77,78 but no prospective clinical 
trials testing these scores have been performed 
yet. In the future, the choice and duration of an­
tiplatelet therapy may be guided more by the gen­
eral patient’s risk profile using the risk scores. In 
case of acute coronary syndromes, it is also pos­
sible that DAPT will change into dual pathway 
regimen combining a novel oral anticoagulant 
with a P2Y12 receptor inhibitor, blocking fibrin 
formation and inhibiting platelet activation and 
aggregation.79
To remember DAPT is mandatory after stent 
implantation for primary prevention of ST and 
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